Salix Coronary Plaque vs AI-ECG Tracker

Similar category, different focus. These tools serve overlapping but distinct needs. Comparability 60/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.

Salix Coronary Plaque

by Artrya

AI-ECG Tracker

by Carewell Health

AI Verdict

Tool A, Salix Coronary Plaque, provides AI-driven analysis of CCTA scans for coronary artery plaque and stenosis, offering detailed anatomical insights into coronary artery disease. In contrast, Tool B, AI-ECG Tracker, focuses on rapid, AI-powered auto-diagnosis of cardiac abnormalities from ECG data, such as arrhythmias and myocardial ischemia. While both are cardiology AI solutions, they utilize different diagnostic modalities and address distinct aspects of cardiac assessment, making them complementary rather than direct competitors.

Choose Salix Coronary Plaque if…

Choose Salix Coronary Plaque if your primary need is a detailed, AI-driven assessment of coronary artery plaque and stenosis directly from CCTA scans. This tool is ideal for cardiologists and radiologists requiring near real-time, point-of-care analysis to identify high-risk plaque features and rapidly diagnose coronary artery disease.

View Salix Coronary Plaque →

Choose AI-ECG Tracker if…

Choose AI-ECG Tracker if your focus is on rapid, AI-powered auto-diagnosis of a wide range of cardiac abnormalities from 12-lead ECG data. This solution is best suited for emergency medicine and cardiology settings where quick identification of conditions like arrhythmias, myocardial ischemia, and infarction is critical, providing comprehensive diagnostic support in approximately three seconds.

View AI-ECG Tracker →

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature	Salix Coronary Plaque	AI-ECG Tracker
Pricing	Subscription model	Unknown
Deployment	Cloud-based (Amazon Web Services), web-based software application	Mobile app, intended for use by qualified healthcare professionals in hospitals and other healthcare facilities.
BAA Available	Yes AI-estimated	Unknown
FDA Status	Yes AI-estimated	Cleared AI-estimated
HIPAA	Unknown	Yes AI-estimated

Head-to-Head

AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.

Usability

Salix Coronary Plaque

Tool A is described as a web-based, cloud-deployed software, which generally offers superior ease of access, simpler setup, and lower IT overhead for users. In contrast, Tool B relies on an on-premise workstation and diagnostic client, potentially requiring more complex installation and maintenance.

Clinical Value

Salix Coronary Plaque

While both tools offer significant clinical value, Tool A provides detailed, quantitative analysis of coronary plaque characteristics from CCTA scans, including the identification of high-risk features like the 'napkin-ring sign'. This offers a deeper and potentially more prognostic insight into coronary artery disease compared to Tool B's broad ECG auto-diagnosis capabilities.

Pricing & Value

Salix Coronary Plaque

Tool A offers transparency by stating a per-scan assessment model linked to a US CPT reimbursement rate of US$950 per assessment, providing a clear understanding of its economic value proposition. Tool B's pricing details are not publicly available, making it difficult for potential customers to assess its value.

Enterprise Readiness

Tie

Both tools are FDA-cleared, a crucial indicator of enterprise readiness. Tool A benefits from cloud deployment and ISO 27001 certification, while Tool B offers flexible on-premise and optional cloud deployment with a dedicated web-based management portal for organizational settings. Both companies indicate strong commitments to data privacy and HIPAA compliance.

Innovation

Salix Coronary Plaque

Both tools leverage AI for diagnostic purposes, but Tool A's capability to identify and quantify specific high-risk coronary plaque features, such as low-attenuation plaque and the napkin-ring sign, from CCTA scans represents a more advanced and nuanced application of AI in cardiovascular diagnostics, pushing the boundaries of non-invasive assessment.

Support & Docs

Tie

Neither the provided structured facts nor general web searches yielded specific details about the level of support, availability of documentation portals, or training resources for either product. Therefore, it is not possible to distinguish between them on this dimension.

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature	Salix Coronary Plaque	AI-ECG Tracker
Product Name	Salix Coronary Plaque	AI-ECG Tracker
Company	Artrya Limited	Shenzhen Carewell Electronics Co.
Primary Data Input	CCTA scans	12-lead ECG data
Core AI Functionality	AI-enabled CCTA analysis for detection and quantification of coronary plaque and stenosis, identification of high-risk plaque features, and quantification of calcifications.	AI-powered ECG auto-analysis and diagnosis for common cardiac abnormalities including arrhythmias, ventricular hypertrophy, myocardial ischemia, and myocardial infarction.
Analysis Speed	Near real-time, point-of-care assessment	Approximately 3 seconds
Specialties	Cardiology, Radiology	Cardiology, Emergency Medicine
Report Generation	Automated report generation (editable)	Window-based professional ECG diagnostic client for review, measurement, annotation, and report generation

Videos

Demos, reviews, and walkthroughs featuring Salix Coronary Plaque and AI-ECG Tracker.

Loading videos…

Videos need JavaScript to load. Search YouTube directly →

View all on YouTube

Frequently Asked Questions

What are the primary clinical applications and diagnostic modalities supported by each tool?

Salix Coronary Plaque is designed for AI-driven assessment of coronary artery plaque and stenosis from CCTA scans, aiding in the rapid and accurate diagnosis of coronary artery disease. AI-ECG Tracker focuses on applying AI technology to 12-lead ECG auto-diagnosis, identifying common cardiac abnormalities such as arrhythmias, ventricular hypertrophy, myocardial ischemia, and myocardial infarction.

What is the reimbursement potential for using these AI tools in a US clinical setting?

Salix Coronary Plaque has a per-scan assessment model with a US CPT reimbursement rate of US$950 per assessment, effective January 1, 2026. For the AI-ECG Tracker, pricing and specific reimbursement details are not publicly available, though other AI-ECG technologies have established Medicare rates.

What specific cardiac conditions or features can each AI tool detect and quantify?

Salix Coronary Plaque detects and quantifies coronary plaque, including high-risk features like low-attenuation plaque and positive remodeling, along with stenosis and calcifications from CCTA scans. AI-ECG Tracker provides comprehensive diagnosis support for 16 cardiac classifications and 104 ECG diagnostic classifications, including arrhythmias, ventricular hypertrophy, myocardial ischemia, and myocardial infarction from 12-lead ECGs.

How quickly do these tools provide diagnostic results?

Salix Coronary Plaque offers near real-time, point-of-care assessment from CCTA scans, with assessments available in less than 10 minutes. The AI-ECG Tracker provides a rapid diagnosis in approximately 3 seconds for ECG auto-analysis.

What are the key differences in how these tools integrate into a physician's workflow?

Salix Coronary Plaque features integrated workflow management and automated, editable report generation for CCTA analysis, without requiring external reading teams. AI-ECG Tracker uses an AI-ECG Workstation, a web-based management portal, and a Windows-based professional ECG diagnostic client for review, measurement, annotation, and report generation.